Seattle Cancer Care Alliance, Seattle, WA.
Division of Hematology, Department of Medicine, University of Washington, Seattle, WA.
JCO Oncol Pract. 2020 Sep;16(9):571-578. doi: 10.1200/OP.20.00241. Epub 2020 May 5.
In January 2020, the first documented patient in the United States infected with severe acute respiratory syndrome coronavirus 2 was diagnosed in Washington State. Since that time, community spread of coronavirus disease 2019 (COVID-19) in the state has changed the practice of oncologic care at our comprehensive cancer center in Seattle. At the Seattle Cancer Care Alliance, the primary oncology clinic for the University of Washington/Fred Hutchinson Cancer Consortium, our specialists who manage adult patients with hematologic malignancies have rapidly adjusted clinical practices to mitigate the potential risks of COVID-19 to our patients. We suggest that our general management decisions and modifications in Seattle are broadly applicable to patients with hematologic malignancies. Despite a rapidly changing environment that necessitates opinion-based care, we provide recommendations that are based on best available data from clinical trials and collective knowledge of disease states.
2020 年 1 月,美国首例经记录的严重急性呼吸综合征冠状病毒 2 型感染患者在华盛顿州被诊断出来。从那时起,该州 2019 年冠状病毒病(COVID-19)的社区传播改变了我们在西雅图综合性癌症中心的肿瘤治疗实践。在西雅图癌症护理联盟,作为华盛顿大学/弗雷德哈钦森癌症研究中心的主要肿瘤诊所,我们管理血液系统恶性肿瘤成年患者的专家迅速调整了临床实践,以降低 COVID-19 对患者的潜在风险。我们认为,我们在西雅图的一般管理决策和修改广泛适用于血液系统恶性肿瘤患者。尽管环境瞬息万变,需要基于意见的护理,但我们提供的建议是基于临床试验的最佳可用数据和疾病状态的集体知识。